NORAD01 - Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE).

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510580-28-00

Enrollment

540

Registered

2024-05-21

Start date

2019-06-05

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Middle or low locally advanced resectable rectal carcinoma

Brief summary

The main endpoint of this phase III study is 3-year progression-free survival from the time to randomization.

Interventions

DRUGOXALIPLATIN

DRUGIRINOTECAN

DRUGFLUOROURACIL

DRUGCALCIUM FOLINATE

DRUGCALCIUM LEVOFOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The main endpoint of this phase III study is 3-year progression-free survival from the time to randomization.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026